ReviewMolecular and cellular endocrinology2008
Pre-receptor regulation of the androgen receptor.
Review in Molecular and cellular endocrinology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- 5-Hydroxyeicosatetraenoic Acid Controls Androgen Reduction in Diverse Types of Human Epithelial Cells.Endocrinology · 2022Article
- Preclinical and Clinical Research Models of Prostate Cancer: A Brief Overview.Life (Basel, Switzerland) · 2022Review
- Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer.Endocrine oncology (Bristol, England) · 2022Review
- The role of adrenal derived androgens in castration resistant prostate cancer.The Journal of steroid biochemistry and molecular biology · 2020Review
- Intracrine androgen biosynthesis and drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes.Endocrine reviews · 2019Review
- AR function in promoting metastatic prostate cancer.Cancer metastasis reviews · 2014Review
- Minireview: Androgen metabolism in castration-resistant prostate cancer.Molecular endocrinology (Baltimore, Md.) · 2013Review
- Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.PloS one · 2013Article
- Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.Scientific reports · 2013Article
- Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.PloS one · 2012Article
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Transcriptional regulation of type 11 17β-hydroxysteroid dehydrogenase expression in prostate cancer cells.Molecular and cellular endocrinology · 2011Article
- Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.The Journal of steroid biochemistry and molecular biology · 2011Review
- Endocrinology of the aging male.Best practice & research. Clinical endocrinology & metabolism · 2011Review
- Hormone response element binding proteins: novel regulators of vitamin D and estrogen signaling.Steroids · 2011Review
- Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2011Article
- "Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2010Review
- Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.PloS one · 2010Article
- New frontiers in androgen biosynthesis and metabolism.Current opinion in endocrinology, diabetes, and obesity · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The human androgen receptor (AR) is a ligand-activated nuclear transcription factor and mediates the induction of genes involved in the development of the male phenotype and male secondary sex characteristics, as well as the normal and abnormal growth of the prostate. We have identified the pair of hydroxysteroid dehydrogenases (HSDs) that regulate ligand access to the AR in human prostate. We find that type 3 3alpha-HSD (aldo-keto reductase (AKR)1C2) catalyzes the NADPH dependent reduction of the potent androgen 5alpha-dihydrotestosterone (5alpha-DHT) to yield the inactive androgen 3alpha-androstanediol (3alpha-diol). We also find that RoDH like 3alpha-HSD (RL-HSD) catalyzes the NAD(+) dependent oxidation of 3alpha-diol to yield 5alpha-DHT. Together these enzymes are involved in the pre-receptor regulation of androgen action. Inhibition of AKR1C2 would be desirable in cases of androgen insufficiency and inhibition of RL-HSD might be desirable in benign prostatic hyperplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.